keyword
MENU ▼
Read by QxMD icon Read
search

sitagliptin

keyword
https://www.readbyqxmd.com/read/28635331/network-meta-analysis-of-liraglutide-versus-dpp-4-inhibitors-for-the-treatment-of-type-2-diabetes-in-japanese-patients
#1
Dieter Ayers, Steve Kanters, Rachel Goldgrub, Monica Hughes, Ryo Kato, Nana Kragh
AIMS: To determine the comparative efficacy and safety of liraglutide and dipeptidyl peptidiase-4 (DPP-4) inhibitors as antidiabetics for Japanese patients with uncontrolled type 2 diabetes (T2DM). METHODS AND MATERIALS: We searched for randomized-controlled trials (RCTs) evaluating outcomes among Japanese adults with uncontrolled T2DM and including liraglutide or DPP-4 inhibitors up to August 2016. We extracted data on trial and patient characteristics, and the following outcomes: HbA1c, weight, patients meeting HbA1c <7%, patients experiencing hypoglycemic events, microalbuminuria, estimated glomerular filtration rate (eGFR) and creatinine...
June 21, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28635324/gliptins-suppress-inflammatory-macrophage-activation-to-mitigate-inflammation-fibrosis-oxidative-stress-and-vascular-dysfunction-in-models-of-non-alcoholic-steatohepatitis-and-liver-fibrosis
#2
Xiaoyu Wang, Michael Hausding, Shih-Yen Weng, Yong Ook Kim, Sebastian Steven, Thomas Klein, Andreas Daiber, Detlef Schuppan
AIMS: Non-alcoholic steatohepatitis (NASH) is characterized by steatosis, panlobular inflammation, liver fibrosis and increased cardiovascular mortality. Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are indirect glucagon like peptide 1 (GLP-1) agonists with antidiabetic and anti-inflammatory activity, used for the treatment of type 2 diabetes. Their potential and underlying mechanisms to treat metabolic liver inflammation and fibrosis as well as the associated vascular dysfunction remain to be explored...
June 21, 2017: Antioxidants & Redox Signaling
https://www.readbyqxmd.com/read/28622738/assessment-of-the-risk-of-hospitalization-for-heart-failure-with-dipeptidyl-peptidase-4-inhibitors-saxagliptin-alogliptin-and-sitagliptin-in-patients-with-type-2-diabetes-using-an-alternative-measure-to-the-hazard-ratio
#3
Masayuki Kaneko, Mamoru Narukawa
BACKGROUND: Saxagliptin statistically significantly increased the risk of hospitalization for heart failure compared with placebo in the clinical trial of SAVOR-TIMI 53. Neither the reason why only saxagliptin among several dipeptidyl peptidase-4 (DPP-4) inhibitors increased the risk, nor the clinical implication of the result has been explained. OBJECTIVE: To evaluate the risk of hospitalization for heart failure associated with DPP-4 inhibitors by using an alternative measure to the hazard ratio...
July 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28618859/sitagliptin-attenuates-endothelial-dysfunction-of-zucker-diabetic-fatty-rats
#4
Huanyuan Wang, Yi Zhou, Zhiying Guo, Yu Dong, Jiahui Xu, Haixia Huang, Huirong Liu, Wen Wang
Although the contributions of sitagliptin to endothelial function in diabetes mellitus were previously reported, the potential mechanisms still remain undefined. Our research was intended to explore the underlying mechanisms of protective effects of sitagliptin treatment on endothelial dysfunction in Zucker diabetic fatty (ZDF) rats. Male lean nondiabetic Zucker rats were used as control and male obese ZDF rats were randomly divided into ZDF and ZDF + sitagliptin groups. The significant decrease in endothelium-dependent relaxation induced by acetylcholine was observed in mesenteric arteries and thoracic aorta rings of ZDF rats...
January 1, 2017: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28611856/a-randomized-controlled-trial-of-vildagliptin-versus-alogliptin-effective-switch-from-sitagliptin-in-patients-with-type-2-diabetes
#5
Erina Shigematsu, Tadashi Yamakawa, Mari S Oba, Jun Suzuki, Jo Nagakura, Kazuaki Kadonosono, Yasuo Terauchi
BACKGROUND: We investigated the effects of vildagliptin or alogliptin on blood glucose and hemoglobin A1c (HbA1c) in patients with type 2 diabetes inadequately controlled by sitagliptin. METHODS: In a single-center open-label trial, 35 patients with inadequate glycemic control on sitagliptin therapy (50 mg once daily) were randomly switched to treatment with vildagliptin (50 mg twice daily) or alogliptin (25 mg once daily). After 12 weeks, patients who failed to achieve the target HbA1c level of < 7...
July 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28599318/sitagliptin-and-oral-cancer-risk-in-type-2-diabetes-patients
#6
Chin-Hsiao Tseng
The reimbursement database of the Taiwan's National Health Insurance was used to evaluate oral cancer risk after sitagliptin use. Patients newly diagnosed of type 2 diabetes during 1999-2008 were recruited. A 1:1 propensity score matched-pair sample of 39195 ever users and 39195 never users were followed up until December 31, 2011. Cox regression incorporated with the inverse probability of treatment weighting using propensity score was used to estimate hazard ratios. Results showed that the overall hazard ratio was not statistically significant (0...
May 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28599244/cb-1r-and-glp-1r-gene-expressions-and-oxidative-stress-in-the-liver-of-diabetic-rats-treated-with-sitagliptin
#7
Zeynep Mine Coskun, Meral Koyuturk, Sezin Karabulut, Sema Bolkent
BACKGROUND: Type 2 diabetes is a major health problem affecting millions of people. Controlled eating and regular physical activity are important for the management of type 2 diabetes. Dipeptidyl peptidase-4 enzyme (DPP-4) inhibitor sitagliptin is a potent agent for the treatment of type-2 diabetes. The aim of this study was to examine the effects of sitagliptin on the liver of rats with streptozotocin (STZ)-induced diabetes, in terms of (i) the expression levels of the cannabinoid 1 receptor (CB-1R) and glucagon-like peptide 1 receptor (GLP-1R), (ii) alterations in the number and localization of these peptides, and (iii) changes in histological and oxidative damage...
March 20, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/28596472/dipeptidyl-peptidase-4-inhibitor-use-is-associated-with-a-lower-risk-of-incident-acute-kidney-injury-in-patients-with-diabetes
#8
Chia-Ter Chao, Jui Wang, Hon-Yen Wu, Kuo-Liong Chien, Kuan-Yu Hung
OBJECTIVES: Dipeptidyl peptidase 4 inhibitor (DPP4i) use potentially slows the progression of diabetic kidney disease, but its effects on the risk of acute kidney injury (AKI) are unclear. We aimed to assess the association between DPP4i use and incident AKI episodes from a nationally representative cohort in Taiwan. MATERIALS AND METHODS: All patients newly diagnosed with diabetes mellitus (DM) between 2008, when DPP4i use was first approved in Taiwan, and mid-2013 were enrolled...
May 23, 2017: Oncotarget
https://www.readbyqxmd.com/read/28592739/a-case-of-idiopathic-normal-pressure-hydrocephalus-in-an-elder-diabetic-patient
#9
Kyoko Kawakami, Hiroshi Yoshino, Hiroyuki Igarashi, Yoshiyuki Chiba, Gen Yoshino, Takahisa Hirose
The clinical entity idiopathic normal pressure hydrocephalus (iNPH) is characterized by dementia, urinary incontinence, gait ataxia. An 80-year old man with a past history of Type 2 diabetes mellitus admitted to our hospital. Combination of twice Aspart and Aspart premixed30/70 insulin were used. Although, he was unable to inject insulin by himself recently. On physical examination, he walked in a mildly wide based manner. According to his family, urinary incontinence was existed. Laboratory data were as follows: Postrandial blood glucose 243 mg/dl and glycated hemoglobin 8...
2017: Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics
https://www.readbyqxmd.com/read/28586742/a-network-meta-analysis-for-efficacy-and-safety-of-seven-regimens-in-the-treatment-of-type-ii-diabetes
#10
Li-Guo Wang, Hui Wang, Qin Liu, Wei-Chang Hua, Chang-Ming Li
The efficacy and safety of seven regimens based on metformin (placebo plus metformin, dapagliflozin plus metformin, vildagliptin plus metformin, saxagliptin plus metformin, empagliflozin plus metformin, exenatide plus metformin and sitagliptin plus metformin) on type 2 diabetes (T2D) were compared based on network meta-analysis. PubMed, Embase and Cochrane Library were applied in the computer-based retrieval process. Randomized controlled trials (RCTs) which were related with the above seven regimens based on metformin in the treatment of T2D were included in this study...
June 3, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28575350/dipeptidyl-peptidase-iv-as-a-prognostic-marker-and-therapeutic-target-in-papillary-thyroid-carcinoma
#11
Jie-Jen Lee, Tao-Yeuan Wang, Chien-Liang Liu, Ming-Nan Chien, Ming-Jen Chen, Yi-Chiung Hsu, Ching-Hsiang Leung, Shih-Ping Cheng
Context: Dipeptidyl peptidase IV (DPP4) is overexpressed in thyroid cancer and certain malignancies. Furthermore, DPP4 has been identified as a discriminatory marker for thyroid cancer. However, it remains unclear whether DPP4 expression plays a prognostic role. Objective: The aim of this study was to investigate the expression and function of DPP4 in thyroid cancer and the mechanisms involved. Design: We determined the expression of DPP4 by immunohistochemistry in tissue microarrays of thyroid tumors...
May 26, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28554326/update-of-cardiovascular-effects-of-older-and-newer-anti-diabetic-medications
#12
Ioanna Eleftheriadou, Pinelopi Grigoropoulou, Evangelos Liberopoulos, Stavros Liatis, Alexandros Kokkinos, Nikolaos Tentolouris
It is known that cardiovascular (CV) disease is the leading cause of morbidity and mortality in individuals with type 2 diabetes. Over the last years one of the most discussed topics is the CV safety of anti-diabetic medications. Regarding CV safety of older anti-diabetic agents the data are less clear and conclusions about their CV safety is based mostly on randomized controlled trials designed to assess their glucose lowering efficacy. In this review we summarize current knowledge about the CV safety of older and newer anti-diabetic medications...
May 29, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28554195/sitagliptin-and-angioedema-a-case-report
#13
Robin Arcani, Sonia Martinez, Stéphane Gayet
No abstract text is available yet for this article.
May 30, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28550195/dipeptidyl-peptidase-4-inhibition-stimulates-distal-tubular-natriuresis-and-increases-in-circulating-sdf-1%C3%AE-1-67-in-patients-with-type-2-diabetes
#14
Julie A Lovshin, Harindra Rajasekeran, Yulyia Lytvyn, Leif E Lovblom, Shajiha Khan, Robel Alemu, Amy Locke, Vesta Lai, Huaibing He, Lucinda Hittle, Weixun Wang, Daniel J Drucker, David Z I Cherney
OBJECTIVE: Antihyperglycemic agents, such as empagliflozin, stimulate proximal tubular natriuresis and improve cardiovascular and renal outcomes in patients with type 2 diabetes. Because dipeptidyl peptidase 4 (DPP-4) inhibitors are used in combination with sodium-glucose cotransporter 2 (SGLT-2) inhibitors, we examined whether and how sitagliptin modulates fractional sodium excretion and renal and systemic hemodynamic function. RESEARCH DESIGN AND METHODS: We studied 32 patients with type 2 diabetes in a prospective, double-blind, randomized, placebo-controlled trial...
May 26, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28539704/comparison-of-antidiabetic-medications-during-the-treatment-of-atherosclerosis-in-t2dm-patients
#15
Xiaojie Liu, Tao Mei, Wei Chen, Shandong Ye
Type 2 diabetes is often associated with arterial atherosclerosis in large blood vessels. We set out to elucidate whether commonly used antidiabetic drugs metformin, sitagliptin, and pioglitazone will reduce atherosclerosis in T2DM patients. We enrolled 176 individuals with type 2 diabetes, which were divided into four treatment groups according to different oral drugs: metformin alone, sitagliptin alone, pioglitazone alone, or combination of metformin and sitagliptin. We assessed changes in glycometabolism, lipid metabolism, cytokine released, and carotid artery intima-media thickness as the readout for improvement in atherosclerosis...
2017: Mediators of Inflammation
https://www.readbyqxmd.com/read/28516377/the-influence-of-sitagliptin-on-treatment-related-quality-of-life-in-patients-with-type-2-diabetes-mellitus-receiving-insulin-treatment-a-prespecified-sub-analysis
#16
Tomoya Mita, Naoto Katakami, Toshihiko Shiraiwa, Hidenori Yoshii, Masahiko Gosho, Hitoshi Ishii, Iichiro Shimomura, Hirotaka Watada
INTRODUCTION: Treatment-related quality of life (QOL) is an important aspect of diabetes management. Here, we investigated the influence of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on treatment-related QOL in patients with type 2 diabetes mellitus treated with insulin. METHODS: This was a prespecified sub-analysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE). The study population consisted of 71 subjects in the sitagliptin group, and 62 subjects in the conventional group who were treated with insulin...
June 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28514822/-cardiovascular-effects-of-antidiabetic-therapies
#17
Katharina Laubner, Jochen Seufert
Type 2- diabetes mellitus (T2DM) represents a major risk factor for cardiovascular complications and mortality. Strict glucose control in the early course of the disease prevents cardiovascular complications only in the long run. Non-medical therapies (diet, exercise, body weight reduction) bear little evidence for positive cardiovascular effects.Bariatric surgery is not number one choice in therapy of T2DM. Metformin seems to provide positive cardiovascular effects. Insulin seems to be cardiovascular neutral, as well as the DPP4-inhibitors Saxagliptin, Sitagliptin and Alogliptin...
May 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/28514518/a-retrosynthesis-approach-for-biocatalysis-in-organic-synthesis
#18
Uwe Bornscheuer, Rodrigo O M A de Souza, Leandro S M Miranda
Lead-In: For the planning of an organic synthesis route, the disconnection approach guided by retrosynthetic analysis of possible intermediates and the chemical reactions involved, back to ready available starting materials, is well established. In contrast, such concepts just get developed for biocatalytic routes. In this review we highlight functional group interconversions catalyzed by enzymes. The article is organized rather by chemical bonds formed - exemplified for C-N, C-O- and C-C-bonds - and not by enzyme classes, covering a broad range of reactions to incorporate the desired functionality in the target molecule...
May 17, 2017: Chemistry: a European Journal
https://www.readbyqxmd.com/read/28511152/-pathogenetic-substantiation-of-complex-treatment-of-nonalcoholic-steatohepatitis-and-steatosis-in-patients-with-pre-diabetes-and-type-2-diabetes
#19
Іван В Чопей, Віталіна В Івачевська, Ксенія І Чубірко, Тарас І Гряділь, Михайло М Гечко
INTRODUCTION: Thesis is devoted to the optimization of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes by acting on carbohydrate and lipid metabolism as well as providing hepatoprotection. AIM: Optimization of diagnostics and treatment in patients treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes. MATERIAL AND METHODS: Examination and treatment of 117 patients with NAFLD and pre-diabetes and type 2 diabetes was performed...
2017: Wiadomości Lekarskie: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/28490565/efficacy-and-safety-of-ipragliflozin-and-metformin-for-visceral-fat-reduction-in-patients-with-type-2-diabetes-receiving-treatment-with-dipeptidyl-peptidase-4-inhibitors-in-japan-a-study-protocol-for-a-prospective-multicentre-blinded-endpoint-phase-iv-randomised
#20
Masaya Koshizaka, Ko Ishikawa, Takahiro Ishikawa, Kazuki Kobayashi, Minoru Takemoto, Takuro Horikoshi, Ryota Shimofusa, Sho Takahashi, Kengo Nagashima, Yasunori Sato, Ichiro Tatsuno, Takashi Terano, Naotake Hashimoto, Nobuichi Kuribayashi, Daigaku Uchida, Koutaro Yokote
INTRODUCTION: In Japan, dipeptidyl peptidase-4 (DPP-4) inhibitors are frequently used as the treatment of choice for patients with type 2 diabetes. In some cases, however, poor glycaemic and body weight control issues persist despite treatment with DPP-4 inhibitors. Previous researchers have revealed that sodium-dependent glucose transporter-2 (SGLT-2) inhibitors reduce both plasma glucose levels and body weight in patients with type 2 diabetes. However, further investigation regarding the effects of SGLT-2 inhibitors on body composition, especially in the Asian population who tends to have relatively low-to-moderate body mass indices, is required...
May 9, 2017: BMJ Open
keyword
keyword
28643
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"